Literature DB >> 25425692

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.

Jaap J Zwaginga1, Bronno van der Holt2, Peter A Te Boekhorst3, Bart J Biemond4, Mark-David Levin5, René van der Griend6, Anneke Brand7, Sonja Zweegman8, Hans F M Pruijt9, Vera M J Novotny10, Art Vreugdenhil11, Marco R de Groot12, Okke de Weerdt13, Elisabeth C M van Pampus14, Tanja M van Maanen-Lamme15, Shulamiet Wittebol16, Martin R Schipperus17, Matthijs H Silbermann18, Peter C Huijgens8, Marleen Luten2, Rene Hollestein2, Jan A C Brakenhoff19, Jolanda G Schrama20, Fransje A A Valster21, Gerjo A Velders22, Harry R Koene13.   

Abstract

Entities:  

Keywords:  early response; immune thrombocytopenia; open label phase II; rituximab; splenectomy delaying

Mesh：

Substances：

Year:  2014        PMID： 25425692      PMCID： PMC4349285          DOI： 10.3324/haematol.2014.110213

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

1.  Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.

Authors:  Zhenyu Li; Weiwei Mou; Guang Lu; Jiang Cao; Xupeng He; Xiuying Pan; Kailin Xu
Journal:  Int J Hematol       Date:  2010-12-29       Impact factor: 2.490

Review 2.  Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Authors:  Donald M Arnold; Francesco Dentali; Mark A Crowther; Ralph M Meyer; Richard J Cook; Christopher Sigouin; Graeme A Fraser; Wendy Lim; John G Kelton
Journal:  Ann Intern Med       Date:  2007-01-02       Impact factor: 25.391

3.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

4.  Low-dose rituximab in adult patients with primary immune thrombocytopenia.

Authors:  Francesco Zaja; Nicola Vianelli; Stefano Volpetti; Marta Lisa Battista; Marzia Defina; Salvatore Palmieri; Monica Bocchia; Marta Medeot; Stefano De Luca; Felicetto Ferrara; Miriam Isola; Michele Baccarani; Renato Fanin
Journal:  Eur J Haematol       Date:  2010-07-28       Impact factor: 2.997

5.  Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.

Authors:  Francesco Zaja; Michele Baccarani; Patrizio Mazza; Monica Bocchia; Luigi Gugliotta; Alfonso Zaccaria; Nicola Vianelli; Marzia Defina; Alessia Tieghi; Sergio Amadori; Selenia Campagna; Felicetto Ferrara; Emanuele Angelucci; Emilio Usala; Silvia Cantoni; Giuseppe Visani; Antonella Fornaro; Rita Rizzi; Valerio De Stefano; Francesco Casulli; Marta Lisa Battista; Miriam Isola; Franca Soldano; Enrica Gamba; Renato Fanin
Journal:  Blood       Date:  2010-02-03       Impact factor: 22.113

6.  The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.

Authors:  Nichola Cooper; Roberto Stasi; Susanna Cunningham-Rundles; Michael A Feuerstein; John P Leonard; Sergio Amadori; James B Bussel
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998

7.  Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.

Authors:  James B Bussel; Christina S Lee; Caroline Seery; Allison A Imahiyerobo; Michaela V Thompson; Diane Catellier; Ithamar G Turenne; Vivek L Patel; Paul A Basciano; Rebecca L Elstrom; Waleed Ghanima
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

8.  Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.

Authors:  Marta Medeot; Francesco Zaja; Nicola Vianelli; Marta Battista; Michele Baccarani; Francesca Patriarca; Franca Soldano; Miriam Isola; Stefano De Luca; Renato Fanin
Journal:  Eur J Haematol       Date:  2008-05-27       Impact factor: 2.997

9.  Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Authors:  Bertrand Godeau; Raphael Porcher; Olivier Fain; François Lefrère; Pierre Fenaux; Stéphane Cheze; Anne Vekhoff; Marie-Paule Chauveheid; Jerôme Stirnemann; Lionel Galicier; Emmanuelle Bourgeois; Stéphanie Haiat; Bruno Varet; Michel Leporrier; Thomas Papo; Mehdi Khellaf; Marc Michel; Philippe Bierling
Journal:  Blood       Date:  2008-05-07       Impact factor: 22.113

10.  Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Giovanni Del Poeta; Elisa Stipa; Maria Laura Evangelista; Margherita M Trawinska; Nichola Cooper; Sergio Amadori
Journal:  Blood       Date:  2007-06-04       Impact factor: 22.113
View more
  5 in total

1.  Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis.

Authors:  Huifeng Zhou; Junjie Fan; Jie He; Shaoyan Hu
Journal:  Ann Hematol       Date:  2022-02-12       Impact factor: 3.673

2.  Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.

Authors:  Howard A Liebman; Mansoor N Saleh; James B Bussel; O George Negrea; Heather Horne; William A Wegener; David M Goldenberg
Journal:  Haematologica       Date:  2016-08-11       Impact factor: 9.941

3.  Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.

Authors:  David E Schmidt; Katja M J Heitink-Polle; Leendert Porcelijn; C Ellen van der Schoot; Gestur Vidarsson; Marrie C A Bruin; Masja de Haas
Journal:  J Thromb Haemost       Date:  2020-04-12       Impact factor: 5.824

Review 4.  Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Authors:  Elisa Lucchini; Francesco Zaja; James Bussel
Journal:  Haematologica       Date:  2019-05-24       Impact factor: 9.941

5.  A functional spleen contributes to afucosylated IgG in humans.

Authors:  Iwona Wojcik; David E Schmidt; David Falck; Gestur Vidarsson; Lisa A de Neef; Minke A E Rab; Bob Meek; Okke de Weerdt; Manfred Wuhrer; C Ellen van der Schoot; Jaap J Zwaginga; Masja de Haas
Journal:  Sci Rep       Date:  2021-12-15       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.